CAR-T Cells Targeting PD-L1 and DLL3 for Small Cell Lung Cancer
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a new CAR-T cell therapy that targets two proteins (PD-L1 and DLL3) on small cell lung cancer cells. It's for people whose cancer came back or got worse after standard chemotherapy, and it aims to see if the treatment is safe and works.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have small cell lung cancer that came back or got worse after one round of platinum-based chemotherapy.
- You need to have at least one tumor that can be measured on a scan (not in the brain).
- You must be between 18 and 70 years old, feeling well enough to do daily activities (ECOG 0-1), and expected to live 3 months or more.
- You cannot have unstable brain metastases, uncontrolled infections, or serious heart or lung problems.
- You cannot have had prior treatment with a DLL3-targeted drug or any CAR-T cell therapy.
- You must agree to use effective birth control during the study and for 6 months after the last treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new type of cell therapy (CAR-T) that targets two proteins, CLDN18.2 and PD-L1, found on some cancer cells. It is for people with advanced solid tumors like stomach, esophageal, or pancreatic cancer that have stopped responding to standard treatments.
This early-phase trial tests CAR-T cells designed to attack tumors that have high HER2 and PD-L1. It may help people with certain solid cancers that have not responded well to standard treatment.
This trial tests a new CAR-T cell therapy (GC511B) for people with a specific type of small cell lung cancer that has DLL3 protein. The treatment uses your own immune cells to target and attack the cancer.
This trial tests a new cell therapy called TC-D101 for people with a type of small cell lung cancer that has DLL3 protein on its surface. It may be an option if standard treatments have stopped working or are not suitable.
This trial tests a new type of immunotherapy called dual-target CAR-NK cells for people with small cell lung cancer that has returned or not responded to treatment. The treatment uses your own immune cells, modified in a lab, to better recognize and attack cancer cells.
This trial tests a new cell therapy that uses your own immune cells to attack cancer. It's for people with small cell lung cancer that has come back or not responded to standard treatments.
Hear when a new Small Cell Lung Cancer Extensive Stage trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.